RT Journal Article
SR Electronic
T1 Transmission dynamics and epidemiological characteristics of Delta variant infections in China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.12.21261991
DO 10.1101/2021.08.12.21261991
A1 Kang, Min
A1 Xin, Hualei
A1 Yuan, Jun
A1 Ali, Sheikh Taslim
A1 Liang, Zimian
A1 Zhang, Jiayi
A1 Hu, Ting
A1 Lau, Eric H. Y.
A1 Zhang, Yingtao
A1 Zhang, Meng
A1 Cowling, Benjamin J.
A1 Li, Yan
A1 Wu, Peng
YR 2021
UL http://medrxiv.org/content/early/2021/08/13/2021.08.12.21261991.abstract
AB Background The Delta variant of SARS-CoV-2 has become predominant globally. We evaluated the transmission dynamics and epidemiological characteristics of the Delta variant in an outbreak in southern China.Methods Data on confirmed cases and their close contacts were retrospectively collected from the outbreak that occurred in Guangdong, China in May-June 2021. Key epidemiological parameters, temporal trend of viral loads and secondary attack rates were estimated and compared between the Delta variant and the wild-type SARS-CoV-2 virus. We also evaluated the association of vaccination with viral load and transmission.Results We identified 167 patients infected with the Delta variant in the Guangdong outbreak. The mean estimates of the latent period and the incubation period were 4.0 days and 5.8 days, respectively. A relatively higher viral load was observed in Delta cases than in wild-type infections. The secondary attack rate among close contacts of Delta cases was 1.4%, and 73.9% (95% confidence interval: 67.2%, 81.3%) of the transmissions occurred before onset. Index cases without vaccination (OR: 2.84, 95% confidence interval: 1.19, 8.45) or with one dose of vaccination (OR: 6.02, 95% confidence interval: 2.45, 18.16) were more likely to transmit infection to their contacts than those who had received 2 doses of vaccination.Discussion Patients infected with the Delta variant had more rapid symptom onset. The shorter and time-varying serial interval should be accounted in estimation of reproductive numbers. The higher viral load and higher risk of pre-symptomatic transmission indicated the challenges in control of infections with the Delta variant.Competing Interest StatementBJC reports honoraria from AstraZeneca, GlaxoSmithKline, Moderna, Roche and Sanofi Pasteur. The authors report no other potential conflicts of interest.Funding StatementThis project was supported by the National Natural Science Foundation of China (No. 82041030); Key-Area Research and Development Program of Guangdong Province (No. 2019B111103001); Theme-based Research Scheme (Project No. T11-712/19-N) of the Research Grants Council of the Hong Kong SAR Government; and a commissioned grant from the Health and Medical Research Fund, Food and Health Bureau, Hong Kong SAR Government.   Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the institutional ethics committee of the Guangdong Provincial Center for Disease Control and Prevention (GDCDC).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to privacy and ethical concerns, the raw data cannot be made available.